A TWO-COHORT, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS, OF EMAPALUMAB IN CHILDREN AND ADULTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN STILL¿S DISEASE (INCLUDING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AND ADULT ONSET STILL¿S DISEASE) OR WITH MAS IN SYSTEMIC LUPUS ERYTHEMATOUS
- Registry ID
- NI-0501-14
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- SWEDISH ORPHAN BIOVITRUM AG (SOBI AG)
- Start date
- 2022-02-08
- Completion date
- 2025-08-15
- Last update
- 2021-08-03
Conditions
Related clinical trials
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS
- A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF ANIFROLUMAB IN ADULTS WITH CHRONIC AND/OR SUBACUTE
CUTANEOUS LUPUS ERYTHEMATOSUS WHO ARE REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL
THERAPY
- A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE 3, LONG-TERM EXTENSION STUDY TO EVALUATE CONTINUOUS SAFETY AND EFFICACY OF BIIB059 (LITIFILIMAB) IN ADULT PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYT
- A PHASE 3 PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SLE
- A MULTICENTER, RANDOMIZED, DOSE-BLIND, PHASE 3 LONG-TERM EXTENSION STUDY TO EVALUATEB CONTINUOUS SAFETY AND EFFICACY OF BIIB059 IN ADULT PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
View on source registry